The Worldwide Intravenous Iron Drugs Industry is Expected to Reach $4 Billion by 2028 – PRNewswire

Share Article

Searching for your content…
In-Language News
Contact Us
888-776-0942
from 8 AM – 10 PM ET
News provided by
Feb 10, 2022, 16:00 ET
Share this article
DUBLIN, Feb. 10, 2022 /PRNewswire/ — The "Intravenous Iron Drugs Market Share, Size, Trends, Industry Analysis Report, By Application, By Products, By Region; Segment Forecast, 2021 – 2028" report has been added to ResearchAndMarkets.com’s offering.
The global intravenous iron drugs market size is expected to reach USD 4.02 billion by 2028 according to a new study. This report gives a detailed insight into current market dynamics and provides analysis on future market growth.

Rising number of clinical trials and growing responsiveness regarding intravenous ferrous drugs by the patients is expected to accelerate the market growth. Moreover, the increasing prevalence of cancer, chronic kidney diseases, and inflammatory bowel disease tied with the escalating investments for the product development activities by the key players may create a lucrative growth of the market over the forecasting years.

Based on application, the chronic kidney disease segment is holding the highest shares in the global industry in 2020, owing to the growing incidences of chronic kidney disease coupled with the increasing demand for intravenous ferrous medications for treating diseases such as urinary tract infections, kidney stones, etc. lead to the demand of the segment around the world.

The demand for the market is rising due to the shifting trend from oral ferrous drugs to intravenous ferrous drugs, along with the launch of first-generation drugs such as Dexeferrum and InfeD. These developments in the medication method offer increased hemoglobin levels, enhance functional capacity, and restore iron.

The major shortcoming of the oral ferrous drug is the chances of severe adverse effects like digestive problems such as vomiting, loss of appetite, constipation, stomach aches, and nausea. The overdose of oral ferrous medications also causes low or fast breathing, pale skin, tiredness or weakness, and bluish fingernails or skin. Therefore, adopting intravenous ferrous drugs helps Erythropoiesis-stimulating Agents (ESAs) perform efficiently to lower anemic conditions. Moreover, it also safeguards an individual’s heart health, which, in turn, stimulates the industry demand in the upcoming years.

Major market participants include Allergan, AbbVie Inc., AMAG Pharmaceuticals, (American Regent. Inc.), American Regent, Inc., Galenica Ltd., Fresenius Medical Care AG & Co. KGaA, Pharmacosmos A/S, Sanofi, Rockwell Medical, Inc., Vifor Pharma Management Ltd, and SHIELD THERAPEUTICS are some of the key players operating in the global industry.

There are numerous industry competitors are introducing innovative products for expanding their business operations around the world. For instance, in July 2021, Sandoz U.S. approval of Ferumoxytol, an intravenous medicine prescribed to treat ferrous deficiency anemia (IDA).
Key Topics Covered:

1. Introduction

2. Executive Summary

3. Research Methodology

4. Intravenous Iron Drugs Market Insights
4.1. Intravenous Iron Drugs Market – Industry snapshot
4.2. Intravenous Iron Drugs Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Rising cases of chronic kidney disorders
4.2.1.2. Prevalence of bowel diseases
4.2.2. Restraints and Challenges
4.2.2.1. Low diagnosis rate
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Intravenous Iron Drugs Market Industry trends
4.6. COVID-19 Impact Analysis

5. Global Intravenous Iron Drugs Market, by Product
5.1. Key Findings
5.2. Introduction
5.2.1. Global Intravenous Iron Drugs Market, by Product, 2016 – 2028 (USD Billion)
5.3. Iron Dextran
5.3.1. Global Intravenous Iron Drugs Market, by Iron Dextran, by Region, 2016 – 2028 (USD Billion)
5.4. Iron Sucrose
5.4.1. Global Intravenous Iron Drugs Market, by Iron Sucrose, by Region, 2016 – 2028 (USD Billion)
5.5. Ferric Carboxymaltose
5.5.1. Global Intravenous Iron Drugs Market, by Ferric Carboxymaltose, by Region, 2016 – 2028 (USD Billion)
5.6. Others
5.6.1. Global Intravenous Iron Drugs Market, by Others, by Region, 2016 – 2028 (USD Billion)

6. Global Intravenous Iron Drugs Market, by Application
6.1. Key Findings
6.2. Introduction
6.2.1. Global Intravenous Iron Drugs Market, by Application, 2016 – 2028 (USD Billion)
6.3. Chronic Kidney Disease
6.3.1. Global Intravenous Iron Drugs Market, by Chronic Kidney Disease, by Region, 2016 – 2028 (USD Billion)
6.4. Inflammatory Bowel Disease
6.4.1. Global Intravenous Iron Drugs Market, by Inflammatory Bowel Disease, by Region, 2016 – 2028 (USD Billion)
6.5. Cancer
6.5.1. Global Intravenous Iron Drugs Market, by Cancer, by Region, 2016 – 2028 (USD Billion)
6.6. Others
6.6.1. Global Intravenous Iron Drugs Market, by Others, by Region, 2016 – 2028 (USD Billion)

7. Intravenous Iron Drugs Market Assessment by Geography

8. Competitive Landscape
8.1. Expansion and Acquisition Analysis
8.1.1. Expansion
8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles
9.1. AbbVie Inc.
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Application Benchmarking
9.1.4. Recent Development
9.2. Allergan
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Application Benchmarking
9.2.4. Recent Development
9.3. AMAG Pharmaceuticals
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Application Benchmarking
9.3.4. Recent Development
9.4. American Regent, Inc.
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Application Benchmarking
9.4.4. Recent Development
9.5. Daiichi Sankyo Company
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Application Benchmarking
9.5.4. Recent Development
9.6. Fresenius Medical Care AG & Co.
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Application Benchmarking
9.6.4. Recent Development
9.7. Galenica Ltd.
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Application Benchmarking
9.7.4. Recent Development
9.8. Pharmacosmos A/S
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Application Benchmarking
9.8.4. Recent Development
9.9. Rockwell Medical, Inc.
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Application Benchmarking
9.9.4. Recent Development
9.10. Sanofi
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. Application Benchmarking
9.10.4. Recent Development
9.11. SHIELD THERAPEUTICS
9.11.1. Company Overview
9.11.2. Financial Performance
9.11.3. Application Benchmarking
9.11.4. Recent Development
9.12. Vifor Pharma Management Ltd.
9.12.1. Company Overview
9.12.2. Financial Performance
9.12.3. Application Benchmarking
9.12.4. Recent Development

For more information about this report visit https://www.researchandmarkets.com/r/da7bb7
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
More news releases in similar topics
Cision Distribution 888-776-0942
from 8 AM – 9 PM ET

source

You might also like

Surviving 2nd wave of corona
COVID-19

Surviving The 2nd Wave of Corona

‘This too shall pass away’ this famous Persian adage seems to be defeating us again and again in the case of COVID-19. Despite every effort

@voguewellness